News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cyto Pulse Sciences, Inc. Working With Walter Reed Army Institute of Research For Dengue Fever Vaccine Delivery Development



10/19/2005 5:09:16 PM

GLEN BURNIE, Md., Sept. 12 /PRNewswire/ -- The Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, has entered into an agreement with Cyto Pulse Sciences, Inc. (Cyto Pulse) of Glen Burnie, MD to develop a DNA vaccine delivery system against Dengue fever.

The agreement, signed in March 2005, is for a three-year project. WRAIR and Cyto Pulse Sciences desire to cooperate in research and development of methods for the administration of Flavivirus (Dengue) vaccines using a pulsed electric field delivery system. The Cyto Pulse Sciences vaccine delivery system uses an array of hundreds of small needles, each one coated with the DNA vaccine. An electric field allows the DNA to enter immune system cells in the skin, specifically the dendritic cells involved in immune system response.

Dengue fever or dengue hemorrhagic fever is a viral disease transmitted by mosquitoes. It is a devastating infection which is rapidly expanding in most tropical and subtropical areas of the world. The CDC calls it the most important arboviral (mosquito or tick-borne) disease of humans.

Work under a previous agreement with WRAIR demonstrated the protective efficacy of a prototype dengue-1 DNA vaccine using electric field-mediated DNA delivery. The new agreement continues that collaboration with testing of an improved, second generation DNA vaccine delivered by Cyto Pulse's new Easy Vax(TM) delivery system.

Cyto Pulse Sciences, Inc. is a medical device company developing and manufacturing systems used in monoclonal antibody production, gene therapy, vaccine production and delivering the new safe DNA/nucleic acid vaccines using its Easy Vax(TM) system. DNA/nucleic acid vaccines provide a total immunity similar to live virus vaccines and are much safer, but they must be delivered directly into the patient's immune system cells. Easy Vax(TM) solves the delivery problem. The company's technology provides the degree of safety, repeatability and efficiency required for commercial and clinical use.

The views expressed are those of the authors and should not be construed to represent the positions of the Department of the Army or Department of Defense.

Additional information on Cyto Pulse Sciences, Inc. is available at the company's website, http://www.cytopulse.com.

CONTACT: Cyto Pulse Science, Inc., +1-410-787-1890.

Cyto Pulse Science, Inc.

CONTACT: Tim Hurd of Cyto Pulse Science, Inc., +1-410-787-1890


Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES